Standard

CXCR4 Is a Potential Target for Anti-HIV Gene Therapy. / Prokopovich, Appolinaria K; Litvinova, Irina S; Zubkova, Alexandra E et al.

In: International Journal of Molecular Sciences, Vol. 25, No. 2, 1187, 01.2024.

Research output: Contribution to journal › Review article › peer-review

Harvard

Prokopovich, AK, Litvinova, IS, Zubkova, AE & Yudkin, DV 2024, 'CXCR4 Is a Potential Target for Anti-HIV Gene Therapy', International Journal of Molecular Sciences, vol. 25, no. 2, 1187. https://doi.org/10.3390/ijms25021187

APA

Prokopovich, A. K., Litvinova, I. S., Zubkova, A. E., & Yudkin, D. V. (2024). CXCR4 Is a Potential Target for Anti-HIV Gene Therapy. International Journal of Molecular Sciences, 25(2), [1187]. https://doi.org/10.3390/ijms25021187

Vancouver

Prokopovich AK, Litvinova IS, Zubkova AE, Yudkin DV. CXCR4 Is a Potential Target for Anti-HIV Gene Therapy. International Journal of Molecular Sciences. 2024 Jan;25(2):1187. doi: 10.3390/ijms25021187

Author

Prokopovich, Appolinaria K ; Litvinova, Irina S ; Zubkova, Alexandra E et al. / CXCR4 Is a Potential Target for Anti-HIV Gene Therapy. In: International Journal of Molecular Sciences. 2024 ; Vol. 25, No. 2.

BibTeX

@article{8aefe7ed21d9410782c1727e23c1a111,
title = "CXCR4 Is a Potential Target for Anti-HIV Gene Therapy",
abstract = "The human immunodeficiency virus (HIV) epidemic is a global issue. The estimated number of people with HIV is 39,000,000 to date. Antiviral therapy is the primary approach to treat the infection. However, it does not allow for a complete elimination of the pathogen. The advances in modern gene therapy methods open up new possibilities of effective therapy. One of these areas of possibility is the development of technologies to prevent virus penetration into the cell. Currently, a number of technologies aimed at either the prevention of virus binding to the CCR5 coreceptor or its knockout are undergoing various stages of clinical trials. Since HIV can also utilize the CXCR4 coreceptor, technologies to modify this receptor are also required. Standard knockout of CXCR4 is impossible due to its physiological significance. This review presents an analysis of interactions between individual amino acids in CXCR4 and physiological ligands and HIV gp120. It also discusses potential targets for gene therapy approaches aimed at modifying the coreceptor.",
keywords = "Humans, Amino Acids, Antifibrinolytic Agents, Epidemics, Genetic Therapy, HIV Infections/genetics, Receptors, CXCR4/genetics, HIV, CXCR4, gene therapy, gp120",
author = "Prokopovich, {Appolinaria K} and Litvinova, {Irina S} and Zubkova, {Alexandra E} and Yudkin, {Dmitry V}",
note = "This work was supported by the Ministry of Science and Higher Education of the Russian Federation (agreement number 075-15-2019-1665).",
year = "2024",
month = jan,
doi = "10.3390/ijms25021187",
language = "English",
volume = "25",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "2",

}

RIS

TY - JOUR

T1 - CXCR4 Is a Potential Target for Anti-HIV Gene Therapy

AU - Prokopovich, Appolinaria K

AU - Litvinova, Irina S

AU - Zubkova, Alexandra E

AU - Yudkin, Dmitry V

N1 - This work was supported by the Ministry of Science and Higher Education of the Russian Federation (agreement number 075-15-2019-1665).

PY - 2024/1

Y1 - 2024/1

N2 - The human immunodeficiency virus (HIV) epidemic is a global issue. The estimated number of people with HIV is 39,000,000 to date. Antiviral therapy is the primary approach to treat the infection. However, it does not allow for a complete elimination of the pathogen. The advances in modern gene therapy methods open up new possibilities of effective therapy. One of these areas of possibility is the development of technologies to prevent virus penetration into the cell. Currently, a number of technologies aimed at either the prevention of virus binding to the CCR5 coreceptor or its knockout are undergoing various stages of clinical trials. Since HIV can also utilize the CXCR4 coreceptor, technologies to modify this receptor are also required. Standard knockout of CXCR4 is impossible due to its physiological significance. This review presents an analysis of interactions between individual amino acids in CXCR4 and physiological ligands and HIV gp120. It also discusses potential targets for gene therapy approaches aimed at modifying the coreceptor.

AB - The human immunodeficiency virus (HIV) epidemic is a global issue. The estimated number of people with HIV is 39,000,000 to date. Antiviral therapy is the primary approach to treat the infection. However, it does not allow for a complete elimination of the pathogen. The advances in modern gene therapy methods open up new possibilities of effective therapy. One of these areas of possibility is the development of technologies to prevent virus penetration into the cell. Currently, a number of technologies aimed at either the prevention of virus binding to the CCR5 coreceptor or its knockout are undergoing various stages of clinical trials. Since HIV can also utilize the CXCR4 coreceptor, technologies to modify this receptor are also required. Standard knockout of CXCR4 is impossible due to its physiological significance. This review presents an analysis of interactions between individual amino acids in CXCR4 and physiological ligands and HIV gp120. It also discusses potential targets for gene therapy approaches aimed at modifying the coreceptor.

KW - Humans

KW - Amino Acids

KW - Antifibrinolytic Agents

KW - Epidemics

KW - Genetic Therapy

KW - HIV Infections/genetics

KW - Receptors, CXCR4/genetics

KW - HIV

KW - CXCR4

KW - gene therapy

KW - gp120

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85183273608&origin=inward&txGid=909b931fea9ede83cbfdc283cbde5127

UR - https://www.mendeley.com/catalogue/bc3e8a61-b920-3a75-a1fd-f968078c41e4/

U2 - 10.3390/ijms25021187

DO - 10.3390/ijms25021187

M3 - Review article

C2 - 38256260

VL - 25

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 2

M1 - 1187

ER -

ID: 60411846